Evaluation of the Abbott RealTi m e CT/NG Assay in Comparison to the Roche Cobas Amplicor CT/NG Assay

Abstract

Several commercial methods exist for the molecular detection of Chlamydia trachomatis and Neisseria gonorrhoeae in clinical samples. Here we evaluated the performance characteristics of the newly FDA-cleared Abbott RealTi m e CT/NG assay (where “CT” stands for Chlamydia trachomatis and “NG” stands for Neisseria gonorrhoeae ) that uses the automated m 2000 molecular platform. Results were compared to those of the Roche Cobas Amplicor CT/NG assay. A total of 926 cervical swab, 45 female urine, 6 male urethral swab, and 407 male urine specimens from 1,384 patients were examined. After resolving all Roche N. gonorrhoeae -positive results with two additional real-time PCR assays, we found that the agreement between the assays was excellent. For urine samples, there was 99.6% positive agreement and 97.7% negative agreement for C. trachomatis , and for male urine samples, there was 100% positive agreement and 99.7% negative agreement for N. gonorrhoeae . For cervical swab samples, there was 98.8% positive agreement and 98.5% negative agreement for C. trachomatis , and there was 96.6% positive agreement and 99.8% negative agreement for N. gonorrhoeae . In limiting dilution analyses, we found that the Abbot assay was more sensitive than the Roche assay for both C. trachomatis and N. gonorrhoeae . In addition, there appeared to be an enhanced ability of the Abbott assay to detect dual infections, especially in the presence of large amounts of N. gonorrhoeae and small amounts of C. trachomatis organisms. In summary, we conclude that the Abbott RealTi m e CT/NG assay is an accurate and automated new addition to the available testing options for C. trachomatis and N. gonorrhoeae .